United States · Bill · S
S. 5123 (117th)
Breakthrough Therapies Act
Introduced
17 November 2022
Last action
—
Status
Read twice and referred to the Committee on the Judiciary.
Sponsors
—
Subjects
Discovery layer
Source updated
10 August 2026
Summary
Breakthrough Therapies Act This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate (text)
Introduced in Senate · EN · 17 November 2022
Introduced in Senate (PDF)
Introduced in Senate · EN · 17 November 2022
Introduced in Senate
summary · EN · 17 November 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/5123
- Open data entity: https://api.congress.gov/v3/bill/117/s/5123